Stockreport

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Ra Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF -Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 [Read more]